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ORIGINAL ARTICLE
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Abstract
Background: The impact of COVID-19 on heart transplant (HTx) recipients remains
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unclear, particularly in the early post-transplant period.
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COVID-19 (three within 2 months post-transplant) from our institution at the epi-
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Methods: We share novel insights from our experience in five HTx patients with
center of the pandemic. Results: All five exhibited moderate (requiring hospitalization, n = 3) or severe (requiring ICU and/or mechanical ventilation, n = 2) illness. Both
cases with severe illness were transplanted approximately 6 weeks before presentation and acquired COVID-19 through community spread. All five patients were on
immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus, and
three that were transplanted within the prior 2 months were additionally on prednisone. The two cases with severe illness had profound lymphopenia with markedly
elevated C-reactive protein, procalcitonin, and ferritin. All had bilateral ground-glass
opacities on chest imaging. MMF was discontinued in all five, and both severe cases
received convalescent plasma. All three recent transplants underwent routine endomyocardial biopsies, revealing mild (n = 1) or no acute cellular rejection (n = 2), and no
visible viral particles on electron microscopy. Within 30 days of admission, the two
cases with severe illness remain hospitalized but have clinically improved, while the
other three have been discharged.
Conclusions: COVID-19 appears to negatively impact outcomes early after heart
transplantation.
KEYWORDS

COVID-19, heart transplant

Abbreviations: AKI, acute kidney injury; ALT, alanine transaminase; ARDS, acute respiratory distress syndrome; AST, aspartate transaminase; COVID-19, Coronavirus disease 2019; CRP,
C-reactive protein; CT, computed tomography; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; EMBx, endomyocardial biopsy; FiO2, fraction
of inspired oxygen; HCQ, hydroxychloroquine; HTx, heart transplant; ICU, intensive care unit; IHC, immunohistochemistry; IL-1, 6, interleukin-1, interleukin-6; ISHLT, International
Society of Heart and Lung Transplantation; LDH, lactate dehydrogenase; LVAD, left ventricular assist device; MMF, mycophenolate mofetil; NRB, non-rebreather; PCR, polymerase
chain reaction; PCWP, pulmonary capillary wedge pressure; PEEP, positive end-expiratory pressure; RHC, right heart catheterization; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
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1 | I NTRO D U C TI O N

clinical severity scale14,20,28: mild (hospitalization not required), moderate (hospitalization), and severe disease (hospitalization plus need

With a mounting death toll approaching 300 000 worldwide,1,2 the

for ICU admission, mechanical ventilation, or death). Baseline char-

COVID-19 pandemic has challenged the global medical community.

acteristics of the COVID-19 HTx patients were also compared to the

A number of studies2-5 have emerged since infection with SARS-

remaining patients who underwent HTx at our center, of which there

CoV-2 was first identified in late 2019, elucidating the natural history

were 31 in total. All patients were counseled to abide by the appro-

and pathophysiology of COVID-19. Mortality rates for COVID-19 di-

priate preventative and quarantine measures. 21,29,30 The Northwell

rectly correlate with advanced age and other comorbid conditions

Health Institutional Review Board approved this case series as

that impart increased cardiovascular risk,4,6-10 such as hypertension,

minimal-risk research using data collected for routine clinical prac-

diabetes, and obesity.11 The question remains whether the infer-

tice and waived the requirement for informed consent (Approval #

ences drawn from these larger studies in the general population can

20-0383).

be extrapolated to immunosuppressed patients, eg, heart transplant
(HTx) recipients, a vulnerable population with a high prevalence of
cardiovascular comorbidities that continue to be present post-HTx.

2.2 | Statistical analysis

Increased risk of severe illness is suggested by a recent study which
reported a mortality rate of 25% among HTx patients with COVID-

For comparison of the baseline patient characteristics in the COVID-

19 in a single transplant center.12 The current prevailing assumption

19 heart transplant cohort vs the uninfected heart transplant pa-

is that immunosuppression is an additive risk that would predispose

tients, Student's t-test and the Fisher's exact test were used for

HTx patients to a more severe disease course. However, the pathog-

continuous and categorical variables, respectively. A P-value of < .05

nomonic inflammatory surge13-15 that actuates severe COVID-19

was considered statistically significant. All analyses were completed

disease could be attenuated in an immunocompromised host po-

using StatsDirect® Statistical Analysis Software.

16

tentially leading to improved outcomes

in some patients. With the

exception of the report by Latif et al,12 the published experience of
COVID-19 in HTx is sparse and largely encapsulated within a broader

2.3 | Analysis of endomyocardial biopsy samples

transplant umbrella encompassing kidney transplant series,17,18 heterogeneous cohorts of solid organ transplants,19,20 and isolated case

Tissue analysis was performed according to our institution's rou-

reports in patients with a remote history of HTx. 21-24

tine protocol for endomyocardial biopsies post-transplant. For this

COVID-19’s established predilection for direct myocardial in-

population, immunohistochemistry (IHC) was performed (in lieu of

jury4,7-9,25-27 warrants a more comprehensive examination focusing

immunofluorescence) on 4-micron-thick sections of formalin-fixed

specifically on HTx cases to improve our understanding of how this

paraffin-embedded tissue using a fully automated system (“Ventana

illness impacts graft function, occurrence of rejection, presence of

Ultra with IVIEW detection kit,” Ventana Medical Systems Inc) and

donor specific antibodies, and other clinical nuances unique to HTx.

the following antibody: C4d (polyclonal, 1:30; Biomedica). To evalu-

Thus, the goal of the present study is to share novel insights from our

ate for the presence of viral particles, tissue was submitted for elec-

experience in five HTx patients with moderate/severe COVID-19 at

tron microscopy and fixed with 2.5% glutaraldehyde in 0.1 mol/L

a large quaternary hospital in the New York City area. Three patients

cacodylate buffer. These were post-fixed in 1% osmium tetroxide,

in this cohort presented with COVID-19 within 6 weeks of trans-

dehydrated in an alcohol gradient, and embedded in an epoxy em-

plant. To the best of our knowledge, the outcomes of HTx patients

bedding medium. One-micron-thick sections were cut and stained

infected with COVID-19 within the early post-transplant period have

with toluidine blue stain. Thin sections were stained with uranyl

not been previously reported, nor have the findings of electron mi-

acetate and lead citrate and examined with a JEOL JEM 100 CXII

croscopy to evaluate direct myocardial involvement of SARS-CoV-2

electron microscope.

in immunosuppressed patients.

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Patient population

3 | R E S U LT S
3.1 | Demographics
The initial characteristics of 5700 patients from Northwell are pre-

We performed a retrospective analysis of all HTx patients trans-

sented elsewhere, 2 and this case series includes in-depth HTx out-

planted at North Shore University Hospital who were alive and at

come results not presented in that study. From March 14 to April

risk of infection from SARS-CoV-2. Infection with SARS-CoV-2 was

19, 2020, five adult HTx recipients with confirmed COVID-19 were

confirmed with nucleic assay microarray analysis of a nasopharyn-

admitted to our institution. Baseline patient characteristics for these

geal specimen. HTx patients infected with SARS-CoV-2 were subdi-

five COVID-19 HTx patients are summarized in Table 1. No mild

vided into one of the three groups according to a previously reported

cases of COVID-19 were observed among our closely followed HTx

|
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Baseline patient characteristics of COVID-19 heart transplant patients by severity of illness
Moderate COVID-19 Disease (N = 3)

Severe COVID-19 Disease (N = 2)

Patient #1

Patient #2

Patient #3

Patient #4

Patient #5

Age (y)

45

68

67

62

68

Sex

Male

Female

Male

Male

Male

Characteristic

Race/Ethnicity

White

Hispanic

Black

Black

White

Body Mass Index (kg/m2)

24.3

27.4

33.0

26.6

33.7

Interval Since Heart
Transplant (d)

13

481

604

45

46

Ischemic Cardiomyopathy
(Pre-HTx)

No

No

Yes

No

Yes

Systemic Hypertension

Yes

Yes

Yes

Yes

Yes

Hyperlipidemia

No

No

Yes

Yes

Yes

Diabetes Mellitus

No

No

No

No

Yes

Obesity (BMI > 30)

No

No

Yes

No

Yes

Post-Transplant Renal
Insufficiency

No

No

Yes

No

Yes

Fever

No

Yes

Yes

No

Yes

Cough

Yes

Yes

Yes

Yes

Yes

Dyspnea

Yes

No

No

Yes

No

Diarrhea

No

Yes

Yes

Yes

Yes

Rigors

No

Yes

Yes

No

No

Days of Symptom Onset to
Test

1

3

2

5

7

Nosocomial COVID-19
Transmission

Yes

No

No

No

No

Comorbidities

Clinical Presentation

Maintenance Immunosuppression at COVID-19 Diagnosis
Prednisone (mg)

30

None

None

15

15

Mycophenolate Mofetil (mg)

2000

500

1000

2000

2000

Tacrolimus (mg)

6

6

10

2

6

Prior Induction Therapy

No

No

No

No

No

Treated Rejection in Past 6 mo

No

No

No

No

No

Temperature (oC)

36.6

36.9

39.3

37.1

36.6

Blood Pressure (mm Hg)

117/58

111/72

126/88

105/78

117/69

Heart Rate (beats/min)

85

102

109

90

78

Respiratory Rate (breaths/min)

18

18

23

43

17

O2 Saturation (%)

95

100

100

86

98

Level of Supplemental O2

Room Air

Room Air

Room Air

15 L NRB

Room Air

White Blood Cell Count (K/µL)

18.2

4.5

4.7

7.4

7.8

Absolute Lymphocyte Count
(#/µL)

850

870

1,260

270

200

Serum Creatinine (mg/dL)

1.4

1.3

1.7

1.9

1.6

eGFR (mL/min/1.73 m2)

60

41

49

43

45

Vital Signs on Presentation

Laboratory Studies on Presentation

(Continues)
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(Continued)
Moderate COVID-19 Disease (N = 3)

Severe COVID-19 Disease (N = 2)

Patient #1

Patient #2

Patient #3

Patient #4

Patient #5

AST/ALT (U/L)

14/16

26/14

16/14

45/30

13/16

Albumin (g/dL)

3.4

4.3

4.0

3.2

3.1

C-Reactive Protein (mg/L)

3.4

2.4

10.7

18.7

16.9

D-Dimer (ng/mL DDU)

2534

n/a

n/a

6000

1194

LDH (U/L)

504

180

222

579

365

Procalcitonin (ng/mL)

n/a

0.1

0.2

5.3

0.72

Ferritin (ng/mL)

163

89

n/a

417

512

Troponin T High Sensitivity
(ng/L)

892

n/a

n/a

111

292

Tacrolimus Trough Level (ng/
mL)

20.4

7.7

8.0

24.0

17.9

recipients (N = 31) as all five SARS-CoV-2 infected patients required

Except for Patient #1 (cough and dyspnea), all of the patients pre-

inpatient management for either moderate (N = 3) or severe (N = 2)

sented with at least three of the aforementioned symptoms. Of

COVID-19 clinical disease. Of these, the majority (80%, Patients

note, both patients with severe disease presented in comparatively

#2-5) were outpatients that developed community-acquired COVID-

delayed fashion (5-7 days) following symptom onset relative to the

19. Patient #1 was still hospitalized from an LVAD explant heart

patients with moderate disease who were diagnosed with COVID-

transplant performed in March 2020 from a confirmed SARS-CoV-2

19 within 72 hours of symptom onset. Only one patient (20%) was

negative donor, when he developed nosocomial COVID-19 infection

febrile on admission (Patient #3) with a temperature of 39.3°C. Only

2 weeks later. Along with Patients #2 and #3 who were both well

one (Patient #4) of the five patients presented with respiratory

over 1 year out from their transplant (481 and 604 days, respec-

distress.

tively), his illness severity did not progress beyond moderate. In contrast, the two patients that developed severe COVID-19 disease had
been transplanted <2 months (45 and 46 days for Patients #4 and

3.3 | Maintenance immunosuppression

#5, respectively) prior to presentation. Two patients had developed
post-transplant renal insufficiency that persisted at the time of their

None of the COVID-19 heart transplant patients had received in-

COVID-19 presentation. All five patients presented with preserved

duction therapy at the time of their transplant. None had more than

graft function.

mild cellular rejection (ISHLT Grade 0 or 1R/1A) in the preceding

Relative to the COVID-19 cohort, the 26 heart transplant pa-

6 months. Patients #2 and #3 were no longer on maintenance steroid

tients in our cohort without clinical evidence of SARS-CoV-2 in-

therapy as they were over 1 year removed from their heart trans-

fection had similar demographics, with no statistically significant

plant. The other three patients were on triple immunosuppressive

differences noted across the following characteristics (uninfected vs

therapy with prednisone, MMF, and tacrolimus upon confirmation

COVID-19 infected): median age (59.6 vs 67.0 years, P = .199), female

of SARS-CoV-2 infection. The average total daily tacrolimus dosage

gender (20% for both groups), race (38.5% vs 40% black, P = 1), body

was 6.0 ± 2.8 mg (range 6-10 mg), and trough level was 15.6 ± 7.4 ng/

mass index (BMI: 25.4 vs 29.0 kg/m2, P = .122), mean number of
days since heart transplant (402.8 vs 237.8 days, P = .28), systemic

mL (range 7.7-24.0) on admission. MMF total daily dose ranged from
500-2000 mg.

hypertension (73% vs 100%, P = .56), hyperlipidemia (19% vs 60%,
P = .09), diabetes mellitus (38.5% vs 20%, P = .63), and renal insufficiency (50% vs 40%, P = 1).

3.4 | Laboratory and imaging studies on
presentation

3.2 | Clinical presentation

Lymphocytic leukopenia was present on admission for the majority of the patients (80%) and most profound in those with severe

The most common presenting symptom for the COVID-19 heart

COVID-19 illness. The majority of the patients (80%) developed

transplant patients was cough (100%) followed by diarrhea (80%),

acute kidney injury (AKI) with decreased eGFR (<50 mL/min/1.73 m2

which was reported in all 4 of the community-acquired cases

for Patients #2-5). Inflammatory biomarkers were elevated in all of

(Patients #2-5). The next most common symptom was fever (60%),

the patients, with the most pronounced CRP derangements again

and both dyspnea and rigors were reported in 40% of the cases.

evident in those with severe COVID-19. These latter two patients

|

LIMA et al.

also presented with marked elevations in procalcitonin, ferritin, and

5 of 8

therapy. Patient #4 also received a single dose of the IL-6 inhibitor

troponin T. It's important to note that while Patient #1 also had an el-

tocilizumab (400 mg) given his tenuous clinical course with progres-

evated troponin T, he was still only 2 weeks removed from his heart

sive worsening of his respiratory failure and escalating inflamma-

transplant and had undergone a routine surveillance endomyocardial

tory biomarkers.

biopsy the day prior to the serum test. All five patients demonstrated
evidence of ground-glass opacities on computed tomographic (CT)
imaging, but infiltrates were only visible on chest x-ray in the two

3.6 | Hemodynamics and histopathology

patients with severe illness.
Patients #1, #4, and #5 were within 2 months of their transplant
and therefore underwent routine scheduled endomyocardial biop-

3.5 | Therapeutic management

sies with hemodynamic assessments. As such, biopsies for all three
of these patients (Table 2) were coincidentally conducted at roughly

In an effort to attenuate the severity of COVID-19 and consistent
with reports from other centers,

21,22,24,29

the immunosuppressive

2 weeks following confirmation of COVID-19 infection. In addition
to evaluating for cellular and humoral rejection by routine H&E and

regimen was modified for each patient (Table 2). MMF was discon-

IHC or immunofluorescence studies, we performed electron micros-

tinued for all five patients, and tacrolimus dosing was decreased

copy on select cases to evaluate for the evidence of direct myocar-

in all except Patient #4, who was already off prednisone. Therapy

dial involvement by coronavirus. Histologic analysis revealed mild

for COVID-19 was dictated by severity of illness and eligibility for

acute cellular rejection (ISHLT grade 1R, Figure 1A) in Patient #1 and

ongoing clinical trials. All three patients with moderate illness re-

no visible cellular rejection (ISHLT grade 0) in Patients #4 and #5.

ceived hydroxychloroquine (HCQ). Patient #1 was also enrolled in

In the case of Patient #1, the preponderance of lymphocytes over

an open-label remdesivir trial (Gilead Sciences) and randomized to

histiocytes or plasma cells and the absence of overt histologic evi-

receive 100 mg of remdesivir intravenously for 10 days. In contrast,

dence of myocyte injury was interpreted to favor rejection over viral

both patients with severe illness received convalescent plasma

myocarditis.

TA B L E 2

Treatment and hospital course for COVID-19 heart transplant patients by severity of illness
Moderate COVID-19 Disease (N = 3)

Severe COVID-19 Disease (N = 2)

Patient #1

Patient #2

Patient #3

Patient #4

Patient #5

MMF Discontinued

Yes

Yes

Yes

Yes

Yes

Tacrolimus Dosing Decreased

Yes

Yes

No

Yes

Yes

Steroid Dosing

Same

N/A

N/A

Increased

Same

HCQ & Remdesivir

HCQ

HCQ

Convalescent Plasma
& Tocilizumab

Convalescent Plasma

1R
Mild Acute Cellular
Rejection

-

-

0R
No Cellular Rejection

0R
No Cellular Rejection

Admission to Intensive Care Unit

No

No

No

Yes

Yes

Invasive Mechanical Ventilation

No

No

No

Yes

Yes

ECMO Support

No

No

No

No

No

Renal Failure Requiring New
Dialysis

No

No

No

Yes

No

Peak Serum Creatinine (mg/dL)

2.0

1.3

1.9

3.9

3.0

Peak C-Reactive Protein (mg/L)

9.2

3.1

10.7

27.9

18.2

Current Status

Discharged Home

Discharged
Home

Discharged
Home

Inpatient

Inpatient

Length of Hospitalization (d)

27

6

23

17

21

Management
Immunosuppression
Modification

COVID-19 Therapy
Histopathology at 2 wka
ISHLT Grade of Biopsy Specimen

Hospital Course

a

Days 14, 11, and 15 following COVID-19 diagnosis and hospitalization.

6 of 8
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F I G U R E 1 Histopathology in Heart Transplant Recipients with COVID-19. Patient #1 underwent routine EMBx 4 wk following cardiac
transplantation (and 2 wk following nosocomial COVID-19 infection). (A) H + E ×200 magnification with focus of ISHLT grade 1R (mild) acute
cellular rejection. Patient #4 was admitted for severe COVID-19 illness 8 wk following cardiac transplantation and underwent EMBx 2 wk
following COVID-19 diagnosis. Histologic analysis of the cardiac biopsy specimens revealed no cellular rejection (ISHLT grade 0) and (B) no
viral particles were seen by assessment with electron microscopy

On the most recent biopsy done prior to discharge from the

RNA remained detectable. Patient #5 developed Staphylococcus

hospital, Patient #1 had no visible rejection (data not shown).

epidermidis bacteremia and required a sternal wound debridement

Immunofluorescence or IHC studies revealed no evidence of anti-

with pectoral muscle flap advancement for management of a deep

body-mediated rejection in any of the specimens, and none of the

sternal wound infection. He also underwent tracheostomy but has

patients formed donor specific antibodies (mean fluorescence inter-

shown similar respiratory improvement and has required only mini-

val 2000) measured on the day of biopsy. Of note, no viral particles

mal periods of ventilatory support. He underwent repeat testing for

were appreciated in any of the biopsy samples evaluated by electron

SARS-CoV-2 on hospital days 36 and 37, and in both cases viral RNA

microscopy (Figure 1B).

was not detected.

By right heart catheterization (RHC), all three patients exhibited normal cardiac outputs and indices that were similar to measurements taken weeks prior to their COVID-19 illness. Patient #5

4 | D I S CU S S I O N

had striking elevations in his filling pressures (RA 19 mm Hg, PCWP
28 mm Hg) that were attributable to acute on chronic renal insuffi-

To the best of our knowledge, this report includes the first HTx pa-

ciency. With aggressive diuresis, his filling pressures improved in the

tients diagnosed with COVID-19 within the early post-transplant

ensuing days as did his renal function.

period and the only histologically documented case of concomitant
acute cellular rejection, albeit mild, in the presence of COVID-19.

3.7 | Hospital course

This report is likewise the first to include invasive hemodynamic data
in patients with moderate/severe COVID-19. Interestingly, the three
patients assessed with RHC (#1, #4-5) had significantly elevated

All three of the heart transplant patients with moderate illness were

troponin levels but preserved cardiac outputs, without arrhythmias,

discharged within 30 days of confirmation of SARS-CoV-2 infection

ischemic EKG changes, or histologically appreciable myocarditis or

(Table 2). Their relatively uneventful clinical course parallels their

detectable viral particles, though tissue evaluation is limited by the

peak CRP levels (mean 7.7 ± 4.0 mg/L), which were substantially less

possibility of sampling bias in this small cohort. Such troponin eleva-

than that of the severe illness patients (mean 23.1 + 6.9 mg/L). Both

tions in the COVID-19 literature have typically heralded significant

patients with severe illness required admission to the ICU and de-

myocardial injury and worse outcome.10,24,26 A plausible mechanism

veloped acute respiratory failure secondary to ARDS requiring me-

for the lack of directly observable myocardial injury may be related

chanical ventilation. At the time of preparing this manuscript, both

to the immunomodulatory protection afforded by the calcineurin in-

patients with severe illness remain hospitalized but have shown evi-

hibitors and other immunosuppression medications administered to

dence of clinical improvement. Two days following treatment with

transplant recipients.16

tocilizumab, the CRP level of Patient #4 decreased to 8.5 mg/L from

Of the 31 HTx recipients in our program, only five had con-

a peak of 27.9 mg/L. He underwent tracheostomy to facilitate venti-

firmed SARS-CoV-2 infection and all developed moderate/severe

lator weaning and developed oliguric renal failure necessitating he-

COVID-19 illness. The two patients with severe disease presented

modialysis, though he has since demonstrated partial renal recovery

in mid-April 2020 and were not included within the recently pub-

and is no longer dependent on hemodialysis. As of hospital day 38,

lished Northwell cohort of 5700 COVID-19 patients admitted to

he has remained been stable for prolonged periods (>24 hours) with-

acute care between March 1, 2020, and April 4, 2020. 2 Relative

out ventilator support. He underwent repeat qualitative nucleic acid

to this larger patient population, progression to respiratory fail-

testing for SARS-CoV-2 on hospital day 34, at which point the viral

ure requiring mechanical ventilation was more common among

|
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the HTx patients with COVID-19 (40% vs 12%). Few of the re-

agents will hopefully become more well defined as published study

maining 26 outpatients have been tested, which is a limitation

data and clinical experiences accumulate.

of this study and raises the possibility of underestimating those

Two critical questions regarding HTx and the COVID-19 pan-

with asymptomatic/mild COVID-19 disease. Nonetheless, the

demic are (a) whether immunosuppression places patients at addi-

low rate of clinically significant COVID-19 in this immunologically

tional risk or perhaps counterintuitively is protective and (b) what

vulnerable cohort speaks to the efficacy of enacted quarantine

are the potential ramifications of continuing to offer transplantation

measures29 and parallels that of the HTx experience reported

while the virus continues to spread in hospitals and the communi-

from Wuhan, China. 30 Though the small number of study patients

ties? Results from our cohort and other published studies point to-

likely precluded statistical significance, it's noteworthy that our

ward immunosuppressed patients having similar or worse outcomes

five patients with COVID-19 moderate/severe illness had a greater

likely due to a blunted immune response17-20,22,23 and would sup-

number of cardiovascular risk factors relative to our stable outpa-

port a very cautious approach to transplantation while the disease

tient HTx recipients, including older age, obesity, hyperlipidemia,

is prevalent. The appropriate management of immunosuppression

and systemic hypertension. Additional studies in larger cohorts of

during COVID-19 infection is unknown at this time but was reduced

HTx patients would help delineate the impact of cardiovascular

in all of our patients and there was no evidence of significant re-

risk factors and susceptibility to COVID-19, as it has for the gen-

jection; this was verified in three patients who underwent endo-

eral population. 2,4,10,11

myocardial biopsies, and by echocardiography all five patients had

The constellation of symptoms exhibited by the COVID-19 HTx

preserved graft function.

12,19,22

HTx during the COVID-19 pandemic poses challenges to the

patients and from non-immunosuppressed individuals. 2 The most

organ procurement team and requires confirmatory negative

critically ill patients (#4-5) were symptomatic for (5-7) days prior

testing of the donor prior to retrieval. 29 Despite utilizing rigor-

to formal, in-person, clinical assessment. The four COVID-19 HTx

ous contact precautions, at least of one our HTx patients con-

patients described in a recent series from Spain also delayed pre-

tracted COVID-19 nosocomially. Of the three patients who were

sentation for close to a week, and only two (50%) survived their hos-

infected within 2 months of transplant and were highly immu-

patients were not dissimilar from those reported in other HTx

pitalizations.19 These findings underscore how insidious progression

nosuppressed, two had severe illnesses requiring intubation and

of SARS-CoV-2 may be of greater concern in immunocompromised

the other had a milder course and never required supplemental

individuals thus warranting vigilant outpatient follow-up to facilitate

oxygen, highlighting the clinical heterogeneity of this disease. As

early identification of COVID-19. Onset of flu-like symptoms should

nosocomial spread is possible and the suggestion that highly im-

raise a high index of clinical suspicion for COVID-19. In such in-

munosuppressed patients may have more severe disease, centers

stances, it may be prudent to have a low threshold for confirmatory

should use caution in pursuing transplantation amidst a pandemic

testing and/or direct physical examination to ensure timely interven-

if viable alternatives exist. Additional experience from our and

tion and supportive care.

other centers will clarify the natural history of COVID-19 in the

Beyond the characteristic lymphopenia present in the majority

immunocompromised host.

of COVID-19 patients, 2,31 the two HTx recipients with severe disease also had profound lymphocytic leukopenia marked by absolute

AC K N OW L E D G E M E N T S

lymphocyte counts (200-270 #/µL) which were substantially lower

The authors gratefully acknowledge the Northwell Covid-19

than any documented thus far in the literature13,15 and potentially

Research Consortium and our Infectious Disease consultant Dr

attributable to myelosuppression from MMF and/or valganciclo-

Marcia Epstein for her input and unwavering commitment to our

vir. The prognostic significance of lymphopenia is well described,

patients.

and coupled with other laboratory study derangements portends a
higher fatality rate. 28 More specifically, both of these patients had

C O N FL I C T S O F I N T E R E S T

advanced to stage III (severe)14 COVID-19 disease with progres-

Dr Maybaum reports grants from Abbot and Abiomed, unrelated to

sion to ARDS and marked elevations in CRP, D-dimer, ferritin, and

this submitted work. Dr Stevens is a consultant for Novartis. The re-

other serum biomarkers indicative of systemic hyperinflammation.

maining authors have no conflicts of interest to disclose. No funding

Along with a steep rise in procalcitonin, these laboratory abnormal-

source was provided for this study.

ities were most pronounced in Patient #4 and may partially explain
why his clinical deterioration was the most precipitous of the study

AU T H O R S C O N T R I B U T I O N S

cohort. Given the favorable response reported in other challenging

All authors listed contributed to the conceptual design of the study,

COVID-19 patients at risk of cytokine storm,32 a single dose of tocili-

interpretation of the data, and data acquisition. Drafting of the man-

zumab was administered and his surrogate markers of inflammation

uscript and subsequent revisions were also areas of contribution by

subsequently decreased over the ensuing days. He remains hospi-

all of the listed co-authors, with BL taking a lead role in manuscript

talized but hemodynamically stable and requires only minimal inter-

writing. All co-authors participated in the final approval of the sub-

mittent ventilatory support. The role of adjunctive antiviral therapy

mitted manuscript for publication and share accountability for the all

with IL-6 and IL-1 receptor antagonists, and other anti-inflammatory

the information included herein.
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